



Ocufen® (flurbiprofen) – Product Discontinuation

- On November 23, 2016, the [FDA announced](#) the discontinuation of Allergan's [Ocufen \(flurbiprofen\)](#) 0.03% ophthalmic solution due to business reasons.
 - Allergan has made a business decision to permanently discontinue manufacturing the branded, authorized generic, and a repackaged version of Ocufen.
 - The discontinuation is not due to product quality, safety or efficacy concerns.
- Ocufen is indicated for the inhibition of intraoperative miosis.
- A generic version of Ocufen is currently available from [Bausch and Lomb](#).



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

Rx News® is published by the OptumRx Clinical Services Department.

©2016 Optum, Inc. All rights reserved.